David B. Beck
David B. Beck | |
---|---|
Born | David Benjamin Beck New Haven, Connecticut, USA |
Nationality | American |
Alma mater | |
Known for | VEXAS Syndrome, Autoinflammatory Disease, Rare Genetic Disease |
Scientific career | |
Fields | Clinical Genetics |
Institutions | |
Doctoral advisor | Danny Reinberg |
Website | https://davidbecklab.org/ |
David B. Beck is an American physician-scientist, clinical geneticist, and researcher who co-discovered VEXAS Syndrome.[1][2][3] He holds dual appointments as an assistant professor in the Department of Medicine and the Department of Biochemistry and Molecular Pharmacology, and is a member of the Center for Human Genetics and Genomics and the Division of Rheumatology at New York University Grossman School of Medicine and NYU Langone Health.[4][5]
Early life and education
[edit]David B. Beck was born in New Haven, Connecticut. He earned his Bachelor of Arts (BA) from Brown University. He would then go on to join the Medical Scientist Training Program (MSTP) at the New York University Grossman School of Medicine. Here he would earn both his PhD (2012) and M.D. (2014).[4] He completed his doctoral thesis in the laboratory of HHMI Investigator Danny Reinberg.[6][7] Beck continued clinical training through the clinician scientist pathway in Internal Medicine at Columbia University and later went on to perform a fellowship in Clinical Genetics jointly at the National Institutes of Health and Johns Hopkins University School of Medicine combined program.[4]
Career
[edit]Following completion of his fellowship, Beck performed postdoctoral research with Daniel L. Kastner at the National Institutes of Health and National Human Genome Research Institute. During his training Beck and colleagues identified a novel inflammatory disorder they called vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic syndrome, or VEXAS syndrome.[1][8][9] In 2021, Beck joined the New York University Grossman School of Medicine faculty where he runs the Inflammatory Diseases Genetic Clinic and his own laboratory where he and his team investigate VEXAS syndrome as well as genetic causes of other disease, with an emphasis on inflammatory diseases and their underlying mechanisms.[10]
References
[edit]- ^ a b Beck, David B.; Ferrada, Marcela A.; Sikora, Keith A.; Ombrello, Amanda K.; Collins, Jason C.; Pei, Wuhong; Balanda, Nicholas; Ross, Daron L.; Ospina Cardona, Daniela; Wu, Zhijie; Patel, Bhavisha (31 December 2020). "Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease". New England Journal of Medicine. 383 (27): 2628–2638. doi:10.1056/NEJMoa2026834. ISSN 0028-4793. PMC 7847551. PMID 33108101.
- ^ Marcela Ferrada, M. D. (2022-01-18). "VEXAS Syndrome". National Institute of Arthritis and Musculoskeletal and Skin Diseases. Retrieved 2023-01-20.
- ^ Azvolinsky, Anna (24 January 2021). "The Vexing VEXAS Syndrome". American Society of Hematology Clinical News.
- ^ a b c "Renowned Clinician-Scientist Joins Division of Rheumatology at NYU Langone Health". finance.yahoo.com. 18 October 2021. Retrieved 18 July 2022.
- ^ Bammert, David (21 June 2022). "The Relapsing Polychondritis Foundation Invests in Potentially Groundbreaking Collaborative Research". polychondritis.org. Relapsing Polychondritis Foundation. Retrieved 19 July 2022.
- ^ Reinberg, Danny (5 May 2014). "Past Students". reinberglab.com. Retrieved 18 July 2022.
- ^ "Danny Reinberg". hhmi.org. Howard Hughes Medical Institute. 17 July 2022. Retrieved 19 July 2022.
- ^ "New inflammatory disease discovered". National Institutes of Health (NIH). 2020-11-02. Retrieved 2022-07-18.
- ^ Leslie, Mitch (23 September 2021). "This genetic sleuth has uncovered a new category of disease marked by sporadic fevers and inflammation". www.science.org. Retrieved 2022-10-18.
- ^ Bammert, David (2022-03-31). "The Relapsing Polychondritis Foundation Invests in the Next Phase of VEXAS Research". The Relapsing Polychondritis Foundation. Retrieved 2022-07-18.
External links
[edit]- Official website
- David B. Beck publications indexed by Google Scholar